181 recruiting. 181 Phase 2, 67 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 181 | Recruiting 181 |
| Phase 1 | 67 | Recruiting 67 |
| Phase 3 | 6 | Recruiting 6 |
Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-11-04 |
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-26 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma Cevostamab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Recruiting | Hoffmann-La Roche | 45 | 2026-11-03 | 2026-11-05 |
| A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma IBI3003 - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Fortvita Biologics (USA)Inc. | 360 | 2026-09-30 | 2026-09-25 |
| CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia CM336, Isatuximab, Bortezomib - Plasma Cell Leukemia (PCL) | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-09-15 | 2026-09-18 |
| CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment CM336 Plus Isatuximab - Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 26 | 2026-09-10 | 2026-09-17 |
| A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma CT0596 - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | UCARsgen Biotech Limited | 68 | 2026-09-03 | 2026-09-17 |
| A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma Elranatamab, Tocilizumab - Multiple Myeloma (MM), Multiple Myeloma Refractory | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 46 | 2026-09-01 | 2026-09-04 |
| BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM) Linvoseltamab - Multiple Myeloma | Phase 2 | Recruiting | Medical College of Wisconsin | 34 | 2026-08-31 | 2026-11-04 |
| A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma AZD4045, Daratumumab, Aldesleukin - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 101 | 2026-07-27 | 2026-10-15 |
| Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Cytokine Release Syndrome, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Naresh Bumma | 35 | 2026-07-17 | 2026-10-06 |
| MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma anti-BCMA/CD3 bispecific antibody - Multiple Myeloma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-07-07 | 2026-08-07 |
| A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma Ramantamig, Tocilizumab, Placebo - Multiple Myeloma | Phase 2 | Recruiting | Janssen Research & Development, LLC | 230 | 2026-06-30 | 2026-11-03 |
| CAR-T in Relapsed/Refractory Multiple Myeloma CAR-T - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Recruiting | Dr. Zaineb Akram | 10 | 2026-06-01 | 2026-07-08 |
| A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). Teclistamab - Multiple Myeloma, AL Amyloidosis | Phase 2 | Recruiting | Shanghai Zhongshan Hospital | 30 | 2026-05-22 | 2026-08-03 |
| Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma Selinexor, Carfilzomib, Isatuximab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Natalie Callander | 62 | 2026-05-21 | 2026-08-31 |
| Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide - Multiple Myeloma | Phase 2 | Recruiting | Eden Biltibo | 50 | 2026-04-20 | 2026-08-19 |
| To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma SG2918 - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Hangzhou Sumgen Biotech Co., Ltd. | 40 | 2026-04-16 | 2026-07-10 |
| A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) Belantamab mafodotin, Dexamethasone, Pomalidomide - Multiple Myeloma | Phase 2 | Recruiting | GlaxoSmithKline | 200 | 2026-04-15 | 2026-08-25 |
Showing 20 of 181. Sign in to see all of them.
Recurrence (24) · Leukemia, Plasma Cell (12) · Leukemia, Myeloid, Acute (10) · Lymphoma, Non-Hodgkin (10) · Neoplasms, Plasma Cell (10) · Neoplasms (9) · Myelodysplastic Syndromes (8) · Hematologic Neoplasms (7) · Hodgkin Disease (7) · Ovarian Neoplasms (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Colorectal Neoplasms (5) · Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4)
Hemic and Lymphatic Diseases (181) · Immune System Diseases (180) · Immunoproliferative Disorders (180) · Hematologic Diseases (179) · Lymphoproliferative Disorders (179) · Neoplasms by Histologic Type (178) · Cardiovascular Diseases (175) · Hemorrhagic Disorders (175) · Hemostatic Disorders (175) · Vascular Diseases (175) · Blood Protein Disorders (174) · Paraproteinemias (174) · Neoplasms (172) · Neoplasms, Plasma Cell (171) · Pathologic Processes (38)
Dexamethasone (49) · Lenalidomide (28) · daratumumab (26) · pomalidomide (19) · Cyclophosphamide (18) · Calcium Dobesilate (17) · carfilzomib (16) · Bortezomib (14) · isatuximab (13) · talquetamab (12) · belantamab mafodotin (10) · fludarabine (10) · Biopsy (9) · Specimen Handling (8) · Magnetic Resonance Spectroscopy (7)
Institute of Hematology & Blood Diseases Hospital, China (14) · M.D. Anderson Cancer Center (6) · Memorial Sloan Kettering Cancer Center (6) · Mayo Clinic (5) · National Cancer Institute (NCI) (5) · Janssen Research & Development, LLC (4) · Regeneron Pharmaceuticals (4) · AbbVie (3) · AstraZeneca (3) · Massachusetts General Hospital (3) · SCRI Development Innovations, LLC (3) · Xuzhou Medical University (3) · Cancer Research UK (2) · Chongqing Precision Biotech Co., Ltd (2) · City of Hope Medical Center (2)
United States (99) · China (54) · Spain (18) · United Kingdom (17) · Australia (13) · Germany (12) · France (11) · South Korea (11) · Canada (10) · Japan (10) · Greece (8) · Israel (7) · Norway (7) · Poland (6) · Belgium (5)
Dickran Kazandjian, MD (3) · Carl O Landgren, MD, PhD (2) · Cheng Qian, PhD (2) · Lugui Qiu (2) · Noopur Raje, MD (2) · Roxana S. Dronca, MD (2) · Sanbin Wang, MD (2) · Ah-Reum Jeong (1) · Ajay K. Nooka, MD,MPH,FACP (1) · Alessandra Larocca (1)
PMID 38826786, PMID 25319501, PMID 27412889, PMID 30352784, PMID 33068284, PMID 33090333, PMID 33717057, PMID 33844595, PMID 35285981, PMID 35537408, PMID 35880941, PMID 36315917, PMID 36753688, PMID 37027810, PMID 37315265, PMID 37393120, PMID 37489819, PMID 37561967, PMID 38039429, PMID 38096472, PMID 38354330, PMID 38402374, PMID 38564684, PMID 38748939, PMID 38816232, PMID 38865672, PMID 38879802, PMID 38992129, PMID 39013131, PMID 39155155, PMID 39167092, PMID 39413339, PMID 40090350, PMID 40558019, PMID 40610648, PMID 40629516, PMID 40631904, PMID 40864183, PMID 41036677, PMID 41100773, PMID 41144785, PMID 41239440, PMID 41313549, PMID 41387038, PMID 41405810, PMID 41429779, PMID 41538762, PMID 41708325, PMID 41719502, PMID 42018965
2023 (7), 2025 (6), 2017 (2), U10CA180820 (2), P30CA033572 (1), P30CA138292 (1), P50CA186781 (1), U10CA180821 (1)